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Abstract 
Objective: ​The Rho GTPase/Rho kinase pathway is an important target in glaucoma treatment. This study 
investigated the ​hypotensive​ effect of RKI-1447, a Rho kinase inhibitor developed for cancer treatment, in a 
porcine ex vivo pigmentary glaucoma model. 
Materials and Methods: ​Twenty-eight fresh porcine anterior chambers were perfused with pigment medium 
(​1.67​×​10​7​ pigment particles/ml​) for 48 hours before being subjected to the RKI-1447 (n=16) or the vehicle 
control (n=12). Another twelve eyes with normal medium perfusion served as the control. The intraocular 
pressure (IOP) was recorded at two-minute intervals and the outflow facility was calculated. To investigate the 
intracellular mechanism of the IOP reduction, primary trabecular meshwork cells were exposed to RKI-1447 or 
the vehicle control and then analyzed for changes in cytoskeleton, motility, and phagocytosis.  
Results: ​Compared to the baseline, the perfusion of pigment caused a significant increase in IOP in the 
RKI-1447 group (P=0.003) at 48 hours. Subsequent treatment with RKI-1447 significantly reduced IOP from 
20.14+/-2.59 mmHg to 13.38+/-0.91 mmHg (​P​=0.02). Pigment perfusion reduced the outflow facility from 
0.27+/-0.03 at baseline to 0.18+/-0.02 at 48 hours (P<0.001). This was partially reversed with RKI-1447. 
RKI-1447 exhibited no apparent changes in the micro- or macroscopic appearance, including histology. 
Primary TM cells exposed to RKI-1447 showed a significant disruption of the actin cytoskeleton both in the 
presence and absence of pigment exposure (P<0.001) but no effect on TM migration was observed. 
Pigment-treated TM cells exhibited a reduction in TM phagocytosis, which RKI reversed.  
Conclusions: ​RKI-1447 is a novel ROCK inhibitor that significantly reduces IOP by disrupting TM stress fibers 
and increasing TM phagocytosis. These features may make it especially useful for the treatment of secondary 
glaucomas with an increased phagocytosis load but also for other open angle glaucomas.  
 
  
Introduction 
The ocular hypertension that is frequently observed in glaucoma patients exhibits a complex pathomechanism 
that remains incompletely understood​1​. The intraocular pressure (IOP) remains the single most important 
modifiable variable in glaucoma treatment​2​. Current topical medications for glaucoma typically increase the 
uveoscleral outflow of aqueous humor (prostaglandin analogues) or reduce aqueous humor production 
(beta-adrenergic blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors). The only drugs that 
increase the conventional outflow that are readily available at the time of this writing are cholinergic agonists 
who have miosis and ciliary spasm as significant side effects​2​ although NO donors are on the horizon that relax 
the TM to increase outflow​3​.​ In the present study we examine the hypotensive effect of RKI-1447, which was 
originally introduced as an anti-tumor agent in breast cancer treatment​4​. 
The Rho-associated protein kinase (ROCK) is part of the serine-threonine kinases that act on the cytoskeleton 
to regulate the movement and shape of cells. It plays a central role in biological functions such as stress-fibre 
formation and contraction, cell adhesion, migration and invasion, transformation, phagocytosis and apoptosis, 
cytokinesis and mitosis as well as differentiation​5,6​. Previous studies found that ROCK is expressed in the TM 
and upregulated in the optic nerve head of glaucomatous eyes​7,8​. Honjo and colleagues found that ROCK 
inhibitor Y-27632 increased the outflow facility in a dose-dependent manner in rabbit eyes​9​. The investigators 
suggested that the hypotensive effect may result from a disruption of actin bundles and reduction in the focal 
adhesion of TM cells​9​. Similarly, recent studies found that ROCK inhibitors disrupt tight junctions thereby 
increasing the permeability of Schlemm’s canal endothelium​10,11​ in addition to decreasing the episcleral venous 
pressure​12​. 
Ripasudil (K-115) was the first approved ROCK inhibitor for glaucoma​13,14​. Two randomized trials involving 413 
Japanese primary open-angle glaucoma patients found that Ripasudil achieved an average of 0.4-1.6 mmHg 
higher IOP reduction than the administration of timolol or latanoprost alone​15​. Phase II/III trials that aim to 
investigate the IOP-lowering effect of four different ROCK inhibitors (AMA0076​16​, AR-13324​17​, K-115​14​ and 
PG-324​18​) are currently in process. Several trials that employed functionally and structurally similar 
compounds were discontinued due to the low therapeutic efficiency and high incidence of adverse events​19​.  
First characterized by Patel et al. in 2012​4​, RKI-1447 inhibits the type I kinase by binding to the ATP binding site 
through interaction with the Asp-Phe-Gly motif and hinge region ​(Figure 1)​4,20​. In vitro, it selectively inhibits 
the ROCK1/2-mediated actin stress fiber formation at the low level of IC-50 (14.5nM and 6.2nM for ROCK1 and 
ROCK2, respectively​21​) following lysophosphatidic acid stimulation. Unlike other ROCK inhibitors, RKI-1447 
does not exhibit cross-reactivity with AKT, MEK, PKA, and PKG signaling, even at a high concentration of up to 
10 ​μ​M​4,21​, reducing the risk of side effects. Recently, our group developed an ex vivo pigmentary glaucoma 
model that exhibited a IOP elevation, a typical TM stress fiber formation, and a reduction in TM 
phagocytosis​22,23​. In this paper, we examine the ocular hypotensive effect of RKI-1447 in an ex vivo anterior 
chamber perfusion model and investigate its possible mechanisms. 
 Figure 1. Molecular structure of RKI-1447.​ RKI-1447 is an ATP site-targeting Rho kinase inhibitor with an IC50 
of 14.5 nM and 6.2 nM for ROCK1 and ROCK2, respectively ​(a)​. It has a crystal structure and works by 
interacting with the Asp-Phe-Gly motif and hinge region of ROCKs ​(b)​.  
 
Materials and Methods 
Pig eye perfusion, pigmentary glaucoma model, and RKI-1447 intervention 
No live animals were involved in the study and the eyes were obtained from a local abattoir. As a result no 
Institutional Animal Care and Use Committee  protocol was required. The setup of the porcine eye perfusion 
system followed our prior protocols ​22,24–26​. Briefly, 40 freshly enucleated pig eyes were obtained from a local 
slaughterhouse (Thoma Meat Market, Saxonburg, PA) and processed within two hours of sacrifice. After the 
removal of extraocular tissues, the eyes were disinfected in a 5% povidone-iodine ophthalmic solution 
(betadine 5%; Alcon, Fort Worth, TX, USA) for two minutes, washed three times with PBS, and hemisected. 
The anterior chambers were then mounted on the perfusion dishes and subsequently underwent continuous 
perfusion with 1% FBS supplemented with DMEM and antibiotics at a constant rate of 3μl per min. 
Once the baseline IOPs were obtained, 28 of the 40 eyes were perfused with the pigment medium for 48 
hours (1.67​×​10​7​ pigment particles/ml) before being subjected to the RKI-1447 (n=16) or the vehicle control 
(n=12). For the RKI-1447 group, RKI-1447 was diluted into the pigment medium to a final concentration of 
1μM before the solution was perfused into the eyes. For the vehicle control, the eyes were continuously 
perfused with the same pigment medium. A total of 12 of the 40 samples without the pigment perfusion and 
the RKI-1447 served as the normal control. IOPs were measured using a pressure transducer at a two-minute 
interval. 
Production of pigment dispersion particles 
Pigment particles for pigment dispersion were produced as previously described using a freeze-thaw 
protocol​25​. In brief, ten porcine irises were sealed in a 50-ml tube, frozen at a temperature of -80° for 2 hours, 
then thawed at room temperature. After two cycles of freeze-thaw, 15 ml of PBS was added to the tube. By 
pipetting up and down 100 times with a 3 ml Pasteur pipette, the pigment particles were shed from the irises. 
They were then collected and centrifuged at 3000 rpm for 15 min. The supernatant was discarded, and the 
pigment pellet was resuspended and centrifuged again at the same settings. Finally, the pigment particles 
were resuspended in 4 ml of phosphate-buffered saline (PBS) as the stock solution and titered using a 
hemocytometer (#1490, Hausser Scientific, Horsham, PA) at 1000-fold dilution as per the method previously 
described​25​. 
Histology 
At the conclusion of the experiments, the chambers were dismounted, washed with PBS, fixed with 4% PFA for 
24 hours and paraffin embedded. The samples were sectioned at 6-micron thickness, followed by staining with 
Hematoxylin and Eosin. 
Primary TM culture 
Primary porcine TM cells were purified and characterized by our previous protocol ​25​. A porcine anterior 
chamber was dissected as above. After removing the extra sclera and cornea, the entire TM stripes were 
sectioned into 1 mm X 1 mm pieces and cultured in a T75 flask with TM-culturing medium (5% FBS 
supplemented with OptiMEM and antibiotics). Primary TM cells started to migrate onto the flask on day four 
and formed clones. The cells were passaged at 80% confluence and replated at a 1:3 ratio. We characterized 
these cells by immunostaining with a combination of TM specific antibodies (alpha smooth muscle actin 
[alpha-SMA] antibody, matrix gla protein [MGP] antibody and aquaporin 1 [AQP1]) and an in vitro phagocytic 
assay. To avoid transformation and differentiation, only the cells within the first four passages were used. 
Immunostaining 
For further characterization, we plated these primary cells onto 10 mm X 10 mm glass slides and fixed them 
with 4% PFA at 80% confluence. This was followed by washing with PBS three times and incubation with the 
primary antibody overnight at 4°. The primary antibodies were goat polyclonal anti-MGP antibodies (1:100 
dilution, sc-32820, Santa Cruz, Dallas, Texas), rabbit polyclonal anti alpha-SMA (1:100, ab5694, Abcam, 
Cambridge, MA) and rabbit polyclonal anti-AQP1 antibodies (1:100, Sc-20810, Santa Cruz, Dallas, Texas). After 
three rinses in PBS, a mixture of secondary antibodies (donkey-anti-goat Alexa Fluor® 647 [1: 200, ab150131, 
Abcam, Cambridge, MA] and goat anti-rabbit Alexa Fluor® 488 [1:1000, A27034, Thermo Scientific, Waltham, 
MA]) was incubated with the cells for 45 minutes at room temperature. The cell nuclei were counterstained 
with DAPI (1: 1000, D1306, Thermo Fisher Scientific, Waltham, MA) for 15 minutes. Images were taken using 
an upright laser scanning confocal microscope at 400x magnification (BX61, Olympus, Tokyo, Japan). 
To quantify the stress fiber formation, the cells were fixed with 4% PFA for 24 hours before being stained with 
Alexa Fluor® 488 Phalloidin for 30 minutes (1:20, A12379, Thermo Scientific, Waltham, MA). The cell nuclei 
were labeled with 4',6-diamidino-2-phenylindole (DAPI). Images were acquired using the upright confocal 
microscope at the same settings as those used to take images of the cell nuclei. Ten randomized visual fields 
were chosen to quantify the percentages of cells with stress fibers for each group. 
TM motility assay 
The in vitro TM cell motility was using a scratch assay with a minor modification​27​. In brief, 2×10​5​ of primary 
TM cells were seeded into each well of a six-well plate and cultured in an environmental chamber that was 
equipped with a digital camera and image acquisition software. After reaching 80% confluency, the cells were 
treated with pigment particle at a concentration of 1.67×10​7 ​particles/ml for 24 hours. A 10μl pipette tip was 
used to create a cell-free scratch that had a consistent width. Following that, RKI-1447 (final concentration: 
1μM) or vehicle was applied. Pictures from ten positions of each well were acquired at a two-hour interval, up 
to 20 hours. The numbers of TM cells moved into the cell-free scratch were counted.  
TM phagocytosis assay 
The phagocytic activity of the primary TM cells was measured by flow cytometry using fluorescence 
microsphere ingestion test​25​. 2×10​5 ​primary TM cells were seeded into each well of a six-well plate and 
underwent the pigment exposure (final concentration: 1.67×10​7 ​particles/ml) or vehicle treatment for seven 
days. Half of the cells were then treated with RKI-1447 (final concentration: 1μM) for 24 hours while the rest 
underwent the sham treatment. To quantify the phagocytic activity, the cells were incubated with 0.5-micron 
fluorescence microsphere at 5×10​8​/ml at 37 degrees for 1 hour. After washing thoroughly with PBS, the cells 
were dissociated with trypsin and resuspended in 200μl PBS for flow cytometry. The percentage of cells 
ingested with microspheres was determined.  
Statistics 
Quantitative data were presented as the mean +/- standard error and processed by PASW 18.0 (SPSS Inc., 
Chicago, IL, USA). A paired t-test was used to compare the IOP responses from the baseline. Other quantitative 
data were compared by one-way ANOVA. A p≤0.05 was considered to be statistically significant.  
 
Results 
IOP reduction and increase of outflow facility 
The baseline IOPs among these three groups were comparable (10.32+/- 0.82 mmHg in the pigment group 
versus 12.21+/-1.06 mmHg in the RKI-1447 group and 10.21+/-1.15 mmHg in the control group, P=0.291). 
Compared to each baseline, the intracameral perfusion of pigment particles resulted in a significant IOP 
elevation in the pigment group (P=0.038) and the RKI-1447 group (P=0.003) at 48 hours, while IOPs in the 
control group remained unchanged (P=0.108). RKI-1447 significantly reduced IOP from 20.14+/-2.59 mmHg to 
13.38+/-0.91 mmHg at 60 hours then remained at a low level throughout the study. In contrast, the IOP in the 
pigment group remained high in comparison to its baseline (all P<0.05). At all time points after RKI-1447, the 
IOP in the RKI-1447 group exhibited no statistical difference compared to the control (all P>0.05); however, 
both were significantly lower than those in the pigment group (all P<0.05) ​(Figure 2 A)​. 
Because the episcleral venous pressure is close to zero in the perfusion system, the outflow facility is inversely 
correlated with IOP. In the current study, the baseline outflow facility exhibited no difference across the three 
groups (P=0.316). Pigment perfusion caused a significant reduction in the outflow facility in the RKI-1447 
group from 0.27+/-0.03 at the baseline to 0.18+/-0.02 at 48 hours (P<0.001), while RKI-1447 partially reversed 
this effect by 14.57% to 48.35% at the follow-up time points. In contrast, the outflow facility in the pigment 
group continuously decreased from a baseline of 0.31+/- 0.03 to 0.15+/-0.01 at the end of the study (all P 
<0.05, compared to its baseline). In the control group, the outflow facility exhibited a slight decrease as the 
time elapsed ​(Fig. 2 B)​. 
 
Figure 2. The changes of intraocular pressure and outflow facility by RKI-1447 treatment. ​IOP at different time points is 
shown. Measurements taken after 48 hrs. after pigment injection revealed that there was a significant increase in IOP in 
the RKI-1447 (P=0.003) and the pigment groups (P=0.038) from their baseline measurements. After treatment with 
RKI-1447, the IOP of the RKI-1447 group decreased significantly from 20.14 +/-2.59 mmHg to 13.38+/-0.91, while the 
pigment group remained significantly higher than its baseline (all P<0.05) ​(A)​.​ ​In the RKI-1447 group, the injection of 
pigment resulted in a significant reduction in outflow facility when measured at 48 hours (P<0.001), which was partially 
reversed after RKI-1447 treatment. In the pigment group, the outflow facility was significantly reduced at all time points 
in comparison to baseline (all P<0.05) ​(B)​. 
TM histology 
Normal TM exhibits a light-pigmented, multilayer, strainer-like structure connected with opening Schlemm's 
canals ​(Figure 3a)​. Consistent with our previous findings​22,25​, pigment perfusion resulted in an increased 
pigmentation in the TM, while most of the pigment particles seemed to be phagocytosed by TM cells without 
physically obstructing the TM ​(Figure 3b)​. RKI-1447 treatment exhibited no apparent changes in TM histology 
(Figure 3c)​. 
 
Figure 3. TM histology. The TM in the control group presented as a lightly-pigmented strainer-like tissue, consisting of 
parallel collagen beams with TM cells ​(left)​. Perfusion with pigment particles resulted in an increase in TM pigmentation 
(middle)​ and was equal to  RKI-1447 exposed eyes  ​(right)​. TM: trabecular meshwork. SC: Schlemm’s canal-like segments 
of the porcine angular aqueous plexus. CE: corneal endothelium. 
Disruption of TM actin stress fibers 
The primary TM cells showed an elongated morphology ​(Figure 4a)​, active phagocytosis​ (Figure 4b)​, and were 
positive for TM-specific markers alpha-SMA, AQP1, and MGP ​(Figures 4c and 4d)​. Pigment exposure did not 
cause an apparent morphological change in TM cells​25​ ​(Figures 4e and 4g)​, while RKI-1447 stimulated a cell 
body contraction within minutes, in the presence or absence of pigment exposure ​(Figures 4f and 4h)​. 
F-actin cytoskeleton labeling with Alexa Fluor® 488 Phalloidin, showed a baseline of 32.57± 2.66 % actin stress 
fibers in normal TM cells, compared to to 67.13± 4.00 % in the pigment-exposed TM cells (P<0.001) ​(Figures 4i 
and 4k)​. RKI-1447 abolished these stress fibers, both in normal TM cells (2.57± 0.86 % versus 32.57± 2.66 %, 
P<0.001) and pigment-exposed TM cells (2.51+/- 0.71 % versus 67.13± 4.00 %, P<0.001) ​(Figures 4j, 4i, and 
4m)​. 
 Figure 4. Primary TM culture, cell morphology, and actin cytoskeleton. ​Primary porcine TM cells were elongated (Figure 
3a) and had an active phagocytic activity (Figure 3b). They tested positive for the TM-specific markers (Figures 3c and 3d) 
AQP1, alpha-SMA, and MGP. Pigment exposure did not stimulate a significant morphological change. Cells contracted 
following RKI-1447 (Figures 3e, 3f, 3g, and 3h). RKI-1447 significantly disrupted the actin cytoskeleton regardless of 
presence or absence of pigment (P<0.001) (Figures 3i, 3j, 3k, 3l, and 3m). 
TM motility 
Since changes in TM movement have been reported in studies of glaucomatous eyes​25,28​, we tested the effect 
of RKI-1447 on TM motility using a modified scratch assay. As shown in Figure 5, the pigment exposure 
statistically decreased the numbers of migrating TM cells (60.83±3.46 in the normal control versus 31.75± 3.36 
cells in the pigment treated group, P<0.001) while RKI-1447 seemed to have no effect on the TM migration, 
either for the normal TM cells or the pigment-treated TM cells (P=0.091 and P=0.398, compared to each 
baseline). 
 
 
Figure 5. RKI-1447 did not effect TM motility.​ The motility of TM cells was measured using a scratch assay with minor 
modification. Compared to the normal control, pigment exposure resulted in a significant reduction in the number of 
migrating TM cells (60.83±3.46 in the control versus 31.75± 3.36 cells in the pigment group, P<0.001). RKI-1447 had no 
significant effect on the TM migration, either for the normal TM cells (P=0.091) or the pigment-treated TM cells 
(P=0.398) in comparison to the baseline. 
Consistent with our previous results​22,25​, pigment exposure caused a reduction in TM phagocytosis by 10.31% 
while RKI-1447 reversed this effect and increased it to 111.52% in comparison to the normal baseline. 
 
Discussion 
Pigmentary glaucoma (PG) is a common type of secondary open-angle glaucoma with an incidence of 
1.4/100,000​29,30​. A readily recognisable feature of this disease is the wide dispersion of pigment in intraocular 
tissues, especially on the corneal endothelium and in trabecular meshwork​31​. Our previous study in a porcine 
eye perfusion model suggested that iris pigment particles induced TM stress fibers, reduced TM phagocytosis, 
adhesion, and motility, and resulted in a significant IOP elevation​25​. In the current study, we found that 
RKI-1447, a ROCK1/ROCK2 inhibitor, efficiently reduced the IOP by 33.58% and increased the outflow facility 
by 38.25% in the same pigmentary glaucoma model. Our in vitro results further revealed that these changes 
might result from the extensive disruption of TM actin stress fibers. 
In the current study, we utilized a porcine anterior segment perfusion model that mimicks the TM changes and 
IOP phenotype of human PG to examine the hypotensive effect of RKI-1447, an oncology drug used in breat 
cancer​4​. Pigment dispersion caused a significant IOP elevation at the 48-hour time interval, while RKI-1447 
partially reversed this effect throughout the study. The TM regulates aqueous outflow by changing its 
cytoskeleton, stiffness, cell adhesion, migration, contraction, and phagocytosis​32,33​, and ROCK signaling plays a 
central role in these processes​7,34​. 
A close interaction between the actin cytoskeleton reorganization, cell or extracellular matrix stiffness, and 
aqueous outflow facility was observed​35,36​. Consistent with our previous work​25​, only a small portion of stress 
fibers formed in the normal TM culture while the pigment exposure increased it by 2.06-fold. Actin stress 
fibers provided a dominant contribution to both cell stiffness and the stiffness of the extracellular matrix​35,37,38 
that directly affected aqueous outflow facility​36​. Gavara et al. also found that the presence of ​aligned and thick 
stress fibers in the cell periphery gave rise to reinforced cell stiffness​39​. In general, factors that induce stress 
fiber formation increase TM stiffness and decrease outflow facility. For example, ​senescence and aging, a risk 
factor for primary open-angle glaucoma, has increases the stress fiber formation and TM stiffness​40​. In a 
different study, dexamethasone, an inducer of cross-linked actin network​41,42​, increased the stiffness of 
primary TM cells and extracellular matrix twofold and fourfold, respectively, after three days​38​, and caused an 
IOP elevation in an ex vivo perfusion model of human eyes​42​. In contrast, numerous reagents have been found 
to disrupt actin stress fiber and exhibit an ocular hypotensive effect. For instance, Y27632, but not 
isoproterenol, pilocarpine, or nifedipine, significantly have been found to abolish cyclic stress-induced stress 
fiber and reverse the elevation of intrachamber pressure​43​. In another study, Rao et al. showed that Y27632 
increased the outflow facility by 40%-80% in pig eyes​43​. Other molecules that target the myosin light chain and 
its kinase have exhibited a similar effect​44–46​. In the current study, RKI-1447 significantly disrupted the stress 
fiber in the pigment-treated TM cells, and the IOP-reducing effect could be at least partially attributed to this. 
As is the case with other ROCK inhibitors​9,46,47​, we found that RKI-1447 caused a significant contraction of TM 
cells. These cells exhibited a round shape and were less adhesive. We also quantified TM motility using live cell 
imaging. The results suggested that the pigment exposure resulted in a significant reduction in TM migration; 
however, it seemed unaffected by RKI-1447, indicating that the IOP-lowering effect might not be directly 
related to TM motility. 
Phagocytosis is driven by a well coordinated rearrangement of the actin cytoskeleton​48,49​. It maintains the 
homeostasis of trabecular outflow by removing the cell debris and melanin from outflow tracts​32,50​. A 
reduction in TM phagocytosis has been observed in various types of glaucoma or glaucoma models. For 
instance, human eye perfusion with dexamethasone for 21 days resulted in a 57% decrease of TM 
phagocytosis without causing a significant loss in TM cells​51​. SWAP70, VASP, and WASP, were believed to play 
an essential role in this process​52​. Consistent with previous studies​22,51​, we found a 10.31% reduction in TM 
phagocytosis following pigment exposure, while RKI-1447 increased it to 111.52% in comparison to the 
control. 
Our study has a number of limitations. First, the anatomical difference between the human and the porcine 
outflow tract and their angular aqueous plexus is significant​53​. Domestic pigs, even ones used as breeders,  are 
not known to  develop glaucoma. A study by Camras et al. suggested that TM stiffness was correlated with 
outflow facility in human eye perfusion but not in the pig specimens​54​. Second, this ex vivo study does not 
account for important factors that can only be examined​ in vivo.​, this study focused on the effect of RKI-1447 
on the TM but is is possible that dilation of post-trabecular outflow tract structures also exhibit a hypotensive 
effect in human open angle glaucoma where a high resistance of often remains after trabecular ablation​55–58​. 
In conclusion, the ROCK inhibitor RKI-1447 reduced IOP in a pigmentary glaucoma model while disrupting TM 
stress fibers and increasing phagocytosis. 
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